Status:

COMPLETED

Inhaled Fentanyl Citrate & Dyspnea

Lead Sponsor:

McGill University

Conditions:

Dyspnea

Eligibility:

MALE

20-40 years

Phase:

EARLY_PHASE1

Brief Summary

"Dyspnea" refers to the awareness of breathing discomfort that is typically experienced during exercise in health and disease. In various participant populations, dyspnea is a predictor of disability ...

Eligibility Criteria

Inclusion

  • Male
  • Aged 20-40 years
  • FEV1 ≥80% predicted
  • FEV1/FVC \>70%

Exclusion

  • Current or ex-smoker
  • Body Mass Index \<18.5 or \>30 kg/m2
  • History of cardiovascular, vascular, respiratory, renal, liver, musculoskeletal, endocrine, neuromuscular and/or metabolic disease/dysfunction
  • Taking doctor prescribed medications
  • History of using pain-relieving (opioid) and/or anti-depressant medications in the previous 6 weeks
  • Allergy to latex
  • Allergy to lidocaine or its "caine" derivatives

Key Trial Info

Start Date :

June 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2014

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT01853449

Start Date

June 1 2013

End Date

August 1 2014

Last Update

February 14 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Montreal Chest Institute; McGill University Health Center & McGill University

Montreal, Quebec, Canada, H2X 2P4

Inhaled Fentanyl Citrate & Dyspnea | DecenTrialz